Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,708 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, Azuma J, Ogihara T, Saruta T, Nakao K; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Ueshima K, et al. Among authors: ogihara t. Contemp Clin Trials. 2009 Jan;30(1):97-101. doi: 10.1016/j.cct.2008.09.006. Epub 2008 Sep 13. Contemp Clin Trials. 2009. PMID: 18824134
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Ogihara T, et al. Hypertension. 2008 Feb;51(2):393-8. doi: 10.1161/HYPERTENSIONAHA.107.098475. Epub 2008 Jan 2. Hypertension. 2008. PMID: 18172059 Clinical Trial.
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T; CASE-J Trial Group. Ogihara T, et al. Hypertens Res. 2008 Aug;31(8):1595-601. doi: 10.1291/hypres.31.1595. Hypertens Res. 2008. PMID: 18971535
1,708 results